Compare Elastic NV (ESTC) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Elastic NV vs Incyte Corporation — how do they compare? Elastic NV trades at $96.33 (market cap $10.00B), while Incyte Corporation trades at $112.56 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 2.3× Elastic NV's market cap, and Elastic NV is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Incyte Corporation for 33 Days on average.
| ESTC | INCY | |
|---|---|---|
Market Cap | $10.00B | $22.85B |
Volume | 1,610,337 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $99.91 | $129.93 |
52-Week Low | $43.30 | $83.80 |
Typical Hold Time | 10 Days | 33 Days |
Enterprise Value | $9.14B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $96.44, up 3.59% today, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent product launches in AI and observability platforms highlight innovation, while profitability metrics show improvement into 2026. The current price sits near resistance at $97, with RSI indicating potential overbought conditions short-term.
Outlook remains positive given earnings momentum and product expansion, but risks include high valuation multiples and insider selling. The consensus price target of $79.50 suggests caution, though bullish sentiment prevails with 65% buy ratings. Investors should weigh growth potential against execution risks in a competitive software market.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
